PMC

Disease-Free Survival (DFS): mastectomy compared to breast conservative therapy; Log-rank test: p = 0.288.

Overall survival (OS): mastectomy compared to breast conservative therapy; Log-rank test: p = 0.173.

Overall survival (OS): difference between the three anthracycline sub-groups: AC60, FEC75, and FAC50; Log-rank test: p = 0.982.

Loco-regional-Free Survival (LRFS): the delay of LRFS was calculated by the date of surgery until the date of revealing of a loco-regional recurrence or until the date of death, or until the date of last news. The median follow-up, the rate of LRFS in five years, and the number of patients censored were presented. Group A (anthracycline): N = 110 (1 events, 109 censored); Group B (CMF): N = 134 (8 events, 126 censored); Survival probability at five years: 98.6% in group A vs 94% in group B; Log-rank test: p = 0.033.

Overall survival (OS): the delay of OS was calculated by the date of histological diagnosis until the death or until the date of last news. The median follow-up, the rate of overall survival in five years, and the number of patients censored were presented. Group A (anthracycline): N = 110 (19 events, 91 censored); Group B (CMF): N = 134 (29 events, 105 censored); Survival probability at five years: 82.5% in group A vs 81.1% in group B; Log-rank test: p = 0.428.

Disease-Free Survival (DFS): the delay of DFS was calculated by the date of surgery until the date of revealing of a progress or until the date of death, or until the date of last news. The median follow-up, the rate of disease free survival in five years, and the number of patients censored were presented. Group A (anthracycline): N = 110 (21 events, 89 censored); Group B (CMF): N = 134 (36 events, 98 censored); Survival probability at five years: 80.4% in group A vs 76.4% in group B; Log-rank test: p = 0.136.